• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Daily aspirin may not improve overall prostate cancer mortality

byMonica ParksandDavid Wang
October 27, 2014
in Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Aspirin use pre- or post-diagnosis of prostate cancer was not significant associated with a decrease in prostate-cancer specific survival.

2. Post-diagnosis daily aspirin use may be associated with increased survival in patients with high-risk prostate cancer.

Evidence Rating Level: 3 (Satisfactory)

Study Rundown: Several observational studies have suggested that aspirin use is associated with reduced prostate cancer specific mortality (PCSM), possibly via inhibition of platelet activation. However, these previous studies have not fully quantified aspirin dosing or frequency, and have had limited sample sizes. The purpose of this prospective cohort trial was to further evaluate the association between pre- and post-diagnosis daily aspirin use with PCSM among men diagnosed with non-metastatic prostate cancer.

This trial prospectively followed over 8000 men with non-metastatic prostate cancer currently on (pre-diagnosis) or starting (post-diagnosis) aspirin therapy. After a mean follow-up of 9 and 6 years for pre- and post-diagnosis respectively, the authors found that aspirin use did not have a statistically significant effect on PCSM, regardless of frequency or level of dosing. However, sub-group analysis demonstrated that post-diagnosis daily aspirin use was associated with lower PCSM among men with high-risk prostate cancer (>T3 and/or Gleason score >8). Interestingly, the protective effect observed was independent of aspirin dosage in the high-risk group. The strengths of this trial were the large sample size and the long period of follow-up. The results of this trial suggest a potential benefit in men with high-risk prostate cancer only; however, additional randomized control trials are required to determine causality of this association.

Click to read the study in Journal of Clinical Oncology

Relevant Reading: Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort

RELATED REPORTS

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

In-Depth [prospective cohort]: The authors of this study identified and ultimately included a total of 8427 men with non-metastatic prostate cancer from the Cancer Prevention Study (CPS)-II Nutrition Cohort. Low-risk prostate cancers were defined as clinical T1-T2 and Gleason score <7, with high risk defined as T>3 or Gleason >8. Information on aspirin dosing (low dose typically 81mg) and frequency of use was reported at enrollment, then on serial follow-up questionnaires every 2 years. The major outcome was prostate cancer-specific mortality (PCSM). Pre-diagnosis daily aspirin use was not significantly associated with PCSM during a mean follow-up of 9.3 years (HR: 0.92; 95% CI: 0.72-1.17), nor was post-diagnosis daily aspirin use during a mean follow-up of 6.4 years (HR: 0.98; 95% CI: 0.74-1.29). PCSM in high-risk prostate cancer was reduced with daily aspirin use (HR: 0.6; 95% CI: 0.37-0.97) with no relationship to dosing (low dose: HR 0.5; 95% CI: 0.27-0.92; high dose: HR 0.73; 95% CI 0.4-1.34).

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: aspirinprostate cancer
Previous Post

Key gut bacteria may prevent Clostridium difficile infection

Next Post

Colleges can support students with chronic medical conditions

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

June 23, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

May 24, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 13, 2022
Next Post
Colleges can support students with chronic medical conditions

Colleges can support students with chronic medical conditions

Enhanced oral patient presentation feedback leads to student improvement

Enhanced oral patient presentation feedback leads to student improvement

New AAP guidelines against albuterol for bronchiolitis

New AAP guidelines against albuterol for bronchiolitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
  • High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
  • Subsidization of supermarkets may help reduce obesity risk in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.